Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial

20252 citationsJournal Articlehybrid Open Access

Authors

Bruce E. Sands · Icahn School of Medicine at Mount Sinai

David T. Rubin · University of Chicago

Edward V. Loftus · Mayo Clinic

Douglas C. Wolf · Atlanta Gastroenterology Associates

Remo Panaccione · Penn West Exploration (Canada)

Jean‐Frédéric Colombel · Icahn School of Medicine at Mount Sinai

Axel Dignaß

Abstract

Ozanimod was effective and safe in biologic-exposed patients with UC, but these patients may require more time to respond to treatment. Clinical trial registry website and trial numbers: ClinicalTrials.gov , numbers NCT02435992 and NCT02531126.

Topics & Keywords

Inflammatory Bowel Disease Acute Lymphoblastic Leukemia research Liver Diseases and Immunity

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The American Journal of Gastroenterology

Volume 120, Issue 10, pp. 2339-2349

DOI: 10.14309/ajg.0000000000003310

Field-Weighted Citation Impact: 3.55